ALX ONCOLOGY HOLDINGS INC cotiza a 1.04 USD y tiene una capitalización bursátil de $144M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06,…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.11 | $-0.15 | $-0.37 |
| Estimado | $-0.16 | $-0.16 | $-0.16 | $-0.32 |
| Sorpresa | — | +31.3% | +6.3% | -15.6% |
| Métrica | ALXO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -391.4% | -40.4% | -351.0% |
| ROA | -172.2% | -32.0% | -140.2% |
| Current Ratio | 2.07 | 2.84 | -0.77 |
| Debt / Equity | 0.39 | 0.28 | +0.11 |